Promising new combo tackles tough leukemia
NCT ID NCT07159620
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a five-drug combination for a rare, aggressive type of T-cell leukemia called ETP-ALL. The study aims to see if this mix can help more patients achieve remission after their first treatment. About 27 newly diagnosed adults will receive the drugs, and researchers will track remission rates, survival, and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax, azacitidine, chidamide, vindesine, and dexamethasone
- What this could lead to
- If successful, this combination could offer a more effective first treatment for a hard-to-treat leukemia, potentially improving remission and survival.
- What could go wrong
- This is a small, early-phase trial with only 27 participants, so results may not apply broadly. The drug combination may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody boost chemotherapy against a rare leukemia?
- Experimental CAR-T therapy targets tough childhood blood cancers
- Massive T-Cell lymphoma database aims to unlock new insights
- Experimental lymphoma drug DS-3201b enters early human testing
- New hope for blood cancer patients in japan?
- Experimental combo targets tough T-Cell lymphoma